Group-specific component and 25-hydroxylase gene polymorphisms in nasopharyngeal carcinoma: Associations with susceptibility and radiotherapy response

doi:10.5306/wjco.v16.i12.111544

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

(51)

(48)

(0)

(553)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Oncol. Dec 24, 2025; 16(12): 111544
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.111544

Table 2 Association between group-specific component and 25-hydroxylase gene polymorphisms and nasopharyngeal carcinoma risk, n (%)

Single nucleotide polymorphism	Types of inheritance	Genotype	Case group	Control group	Odds ratio (95%CI)	P value
GC rs4588	Codominant	GG	156 (43.3)	272 (49.5)	1.00 (reference)
		GT	152 (42.2)	230 (41.8)	1.15 (0.87-1.53)	0.325
		TT	52 (14.5)	48 (8.7)	1.68 (1.15-2.45)	0.007
	Dominant (TT + GT vs GG)	TT + GT	204 (56.7)	278 (50.5)	1.28 (0.98-1.67)	0.071
	Dominant (TT + GT vs GG)	GG	156 (43.3)	272 (49.5)	1.00 (reference)
	Recessive (TT vs GT + GG)	TT	52 (14.5)	48 (8.7)	1.56 (1.02-2.38)	0.039
	Recessive (TT vs GT + GG)	GT + GG	308 (85.5)	502 (91.3)	1.00 (reference)
GC rs7041	Codominant	CC	132 (36.7)	214 (38.9)	1.00 (reference)
		CA	168 (46.7)	258 (46.9)	1.06 (0.79-1.41)	0.713
		AA	60 (16.6)	78 (14.2)	1.24 (0.83-1.85)	0.287
	Dominant (AA + CA vs CC)	AA + CA	228 (63.3)	336 (61.1)	1.10 (0.84-1.44)	0.498
	Dominant (AA + CA vs CC)	CC	132 (36.7)	214 (38.9)	1.00 (reference)
	Recessive (AA vs CA + CC)	AA	60 (16.6)	78 (14.2)	1.21 (0.84-1.74)	0.309
	Recessive (AA vs CA + CC)	CA + CC	300 (83.4)	472 (85.8)	1.00 (reference)
CYP2R1 rs10741657	Codominant	GG	168 (46.7)	242 (44.0)	1.00 (reference)
		GA	148 (41.1)	246 (44.7)	0.87 (0.66-1.15)	0.326
		AA	44 (12.2)	62 (11.3)	1.02 (0.66-1.58)	0.924
	Dominant (AA + GA vs GG)	AA + GA	192 (53.3)	308 (56.0)	0.90 (0.69-1.17)	0.423
	Dominant (AA + GA vs GG)	GG	168 (46.7)	242 (44.0)	1.00 (reference)
	Recessive (AA vs GA + GG)	AA	44 (12.2)	62 (11.3)	1.09 (0.73-1.65)	0.673
	Recessive (AA vs GA + GG)	GA + GG	316 (87.8)	488 (88.7)	1.00 (reference)
CYP2R1 rs12794714	Codominant	GG	152 (42.2)	250 (45.5)	1.00 (reference)
		GA	160 (44.5)	238 (43.3)	1.10 (0.83-1.46)	0.492
		AA	48 (13.3)	62 (11.2)	1.27 (0.83-1.95)	0.273
	Dominant (AA + GA vs GG)	AA + GA	208 (57.8)	300 (54.5)	1.14 (0.87-1.49)	0.339
	Dominant (AA + GA vs GG)	GG	152 (42.2)	250 (45.5)	1.00 (reference)
	Recessive (AA vs GA + GG)	AA	48 (13.3)	62 (11.2)	1.21 (0.81-1.81)	0.356
	Recessive (AA vs GA + GG)	GA + GG	312 (86.7)	488 (88.8)	1.00 (reference)

CYP2R1: 25-hydroxylase; GC: Group-specific component.

Full Size Table

Citation: Liu L, Shi DY, Tan J, Xu S, Liu CR. Group-specific component and 25-hydroxylase gene polymorphisms in nasopharyngeal carcinoma: Associations with susceptibility and radiotherapy response. World J Clin Oncol 2025; 16(12): 111544
URL: https://www.wjgnet.com/2218-4333/full/v16/i12/111544.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i12.111544

Liu L, Shi DY, Tan J, Xu S, Liu CR. Group-specific component and 25-hydroxylase gene polymorphisms in nasopharyngeal carcinoma: Associations with susceptibility and radiotherapy response. World J Clin Oncol 2025; 16(12): 111544 [PMID: 41480174 DOI: 10.5306/wjco.v16.i12.111544]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.